The first wave of generic versions of Novo Nordisk’s GLP-1 weight-loss drugs has launched in India, with at least five domestic drug manufacturers offering prices up to 80% lower than the original. This development follows the expiration of Novo’s patent on Friday, as the company aims to maintain its position in a critical market that has around 100 million people living with diabetes and a significant obesity rate.
Sun Pharmaceutical has introduced a generic version of semaglutide for as low as 750 rupees ($8) per weekly injection, compared to Novo’s retail price of between 8,800 and 10,000 rupees. Dr. Reddy’s Laboratories has launched semaglutide at approximately 4,200 rupees per month, aiming to expand its market presence internationally.
More than 50 brands are anticipated to release generic semaglutide in the upcoming months, although the complex nature of producing these drugs may limit the number of manufacturers capable of meeting quality standards. Indian companies, such as Natco Pharma and Alkem Laboratories, have also entered the market with competitive pricing strategies.
In the U.S., semaglutide remains protected from generic competition until 2032, but patent expirations in multiple countries this year could significantly affect Novo’s revenue. Analysts suggest that if Novo cuts prices in India, it may retain a sizable market share, although the generic competition is expected to challenge its dominance considerably.
Novo has recently reduced the price of its obesity drug, Wegovy, by 37% in India prior to the patent expiration. The company is implementing strategies to defend its premium brand against cheaper generics, including partnerships with local firms for enhanced market access.
The growing popularity of GLP-1 drugs has been significant, with sales in India increasing rapidly. However, price remains a major barrier to access; experts indicate that a substantial portion of patients could benefit from these medications if they were more affordable.
Manufacturing semaglutide requires specialized technology and stringent quality control, which presents challenges for Indian generics. Despite progress in the sector, experts express concerns about maintaining product quality compared to international standards, and some analysts warn against the potential proliferation of generics in markets where patents remain in force.
Source: Reported based on publicly available information from www.cnbc.com.
